ARCHIVES

Government Offers Two Approval Standards For Assays: CLIA, FDA

This article is from The Cancer Letter archive.

Vol. 35 No. 04 | January 30, 2009

Download PDF Visit The Full Archive

Related Articles

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

October 25, 2013

Particle Therapy Program Would cost $600 million Over 10 Years for 16 Facilities, Clinical Trials

December 2, 1977

CCRU-CCSP Report At Closed Session “Declassified” Discusses Review

December 3, 1982

NRC considering “Escalated” Enforcement Action Against NIH

February 2, 1996

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

Severe Shortages Of Many Cancer Drugs Affecting Practices

November 19, 2010